Key result
Evogliptin proves non-inferior to sitagliptin or linagliptin for HbA1c reduction in type 2 diabetes.
Why the study?
The comparative efficacy and safety of evogliptin versus other DPP-4 inhibitors for HbA1c reduction and adverse events in T2DM patients were not clearly established.
Does evogliptin improve HbA1c levels and reduce adverse events in patients with type 2 diabetes mellitus compared to sitagliptin and linagliptin?
Meta-Analysis (n=845)
Does evogliptin improve HbA1c levels and reduce adverse events in patients with type 2 diabetes mellitus compared to sitagliptin and linagliptin?
Mean Difference: 0.062 (95% CI -0.092–0.215)
p-value: p=0.431
Evogliptin demonstrates similar efficacy in reducing HbA1c levels and a comparable safety profile to other DPP-4 inhibitors like sitagliptin and linagliptin in patients with type 2 diabetes mellitus.
Supports evogliptin as interchangeable second-line T2DM therapy; extends comparative DPP-4i efficacy and safety data.
Introduction The dipeptidyl peptidase-4 inhibitor (DPP-4i) drugs, such as evogliptin, as the second-line drugs for type 2 diabetes mellitus (T2DM) treatment have been reported to facilitate insulin secretion by reducing glucagon and inhibiting glucagon like peptides. With a vague consensus, the advantageous and non-inferior effects of evogliptin relative to other DPP-4i drugs were recently demonstrated on hemoglobin A1c (HbA1c) levels and overall adverse events in T2DM patients. Thus, the aim was to evaluate the overall influence of evogliptin on HbA1c levels and the adverse events in T2DM patients compared to sitagliptin and linagliptin. Methods Complying with PRISMA guidelines, we conducted a systematic literature search in databases and a meta-analysis. Data about HbA1c levels and the adverse events of T2DM patients were collected and analyzed. Results From 1,397 studies, we found five matched studies involving 845 subjects (mean age: 54.7 ± 3 years). The meta-analysis revealed that evogliptin was non-inferior to sitagliptin/linagliptin with a mean difference of 0.062 (95% CI: -0.092 to 0.215. I2: 0%. P = 0.431) regarding the HbA1c level reduction, and the risk ratio was -0.006 (95% CI: -0.272 to 0.260. I2: 1.7%. P = 0.966) regarding the adverse effects, indicating no significant difference between evogliptin and linagliptin or sitagliptin in affecting the HbA1c level and adverse effects. Conclusion The study provides preliminary evidence regarding the similarity in the efficacy of evogliptin compared to other DPP-4i drugs, including sitagliptin and linagliptin, for managing HbA1c levels and adverse events.
No takes yet. Share an insight, caveat, or question.
Tang et al. (2022) conducted a meta-analysis in Type 2 diabetes mellitus (n=845). Evogliptin vs. Sitagliptin or Linagliptin was evaluated on HbA1c level reduction (MD 0.062, 95% CI -0.092 to 0.215, p=0.431). Evogliptin was non-inferior to sitagliptin or linagliptin in reducing HbA1c levels in patients with type 2 diabetes mellitus, with a mean difference of 0.062 (95% CI: -0.092 to 0.215).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: